

# David S Hong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1782987/publications.pdf>

Version: 2024-02-01

209  
papers

17,649  
citations

25014

57  
h-index

16164

124  
g-index

213  
all docs

213  
docs citations

213  
times ranked

23811  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Larotrectinib in <i>TRK</i> Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	13.9	2,036
2	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. <i>Nature</i> , 2019, 575, 217-223.	13.7	1,375
3	KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049
4	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 180-188.	1.2	647
5	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	5.1	608
6	Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2660-2666.	0.8	504
7	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 122, 1630-1637.	2.9	472
8	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. <i>Clinical Cancer Research</i> , 2012, 18, 6373-6383.	3.2	458
9	Interleukin-6 and its receptor in cancer. <i>Cancer</i> , 2007, 110, 1911-1928.	2.0	356
10	AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer. <i>Science Translational Medicine</i> , 2015, 7, 314ra185.	5.8	352
11	Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. <i>Cancer Immunology Research</i> , 2014, 2, 831-838.	1.6	270
12	<i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. <i>Cancer Research</i> , 2013, 73, 276-284.	0.4	262
13	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396.	3.2	261
14	Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 3557-3565.	0.8	258
15	Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. <i>Cancer Treatment Reviews</i> , 2013, 39, 375-387.	3.4	217
16	Targeting TRK family proteins in cancer. , 2017, 173, 58-66.		217
17	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.	7.7	192
18	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 3396-3406.	3.2	188

#	ARTICLE	IF	CITATIONS
19	Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model. <i>American Journal of Pathology</i> , 2006, 168, 962-972.	1.9	186
20	MABp1, a first-in-class true human antibody targeting interleukin-1 $\beta$ in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. <i>Lancet Oncology</i> , The, 2014, 15, 656-666.	5.1	178
21	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. <i>PLoS ONE</i> , 2011, 6, e22769.	1.1	174
22	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). <i>Journal of Clinical Oncology</i> , 2021, 39, 285-294.	0.8	169
23	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	168
24	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. <i>Journal of Translational Medicine</i> , 2016, 14, 339.	1.8	167
25	STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. , 2018, 6, 119.		165
26	Deep Learning-Assisted Diagnosis of Cerebral Aneurysms Using the HeadXNet Model. <i>JAMA Network Open</i> , 2019, 2, e195600.	2.8	163
27	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	0.8	149
28	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2021, 11, 80-91.	7.7	148
29	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 115-124.	5.1	147
30	Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRAS <sup>G12C</sup> inhibitor, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3003-3003.	0.8	145
31	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv253.	3.0	139
32	Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1 "2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 383-393.	5.1	131
33	RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. <i>Cancer Treatment Reviews</i> , 2016, 50, 35-47.	3.4	128
34	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 181-188.	3.2	127
35	Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins. <i>Clinical Cancer Research</i> , 2018, 24, 5807-5814.	3.2	119
36	Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse. <i>Clinical Cancer Research</i> , 2010, 16, 1289-1297.	3.2	114

#	ARTICLE	IF	CITATIONS
37	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
38	A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer. Clinical Cancer Research, 2011, 17, 6582-6591.	3.2	109
39	BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency. Clinical Cancer Research, 2012, 18, 2326-2335.	3.2	109
40	Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. , 2020, 8, e000537.		105
41	Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 997-1005.	1.8	100
42	P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. Oncotarget, 2013, 4, 705-714.	0.8	96
43	Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer, 2012, 118, 1422-1428.	2.0	88
44	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget, 2015, 6, 12809-12821.	0.8	86
45	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunology Research, 2019, 7, 1903-1909.	1.6	86
46	Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980.	1.0	83
47	Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2017, 35, 1304-1311.	0.8	82
48	Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer, 2005, 104, 1620-1626.	2.0	80
49	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
50	Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies. Clinical Cancer Research, 2009, 15, 7061-7068.	3.2	78
51	Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clinical Cancer Research, 2012, 18, 2922-2929.	3.2	78
52	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404.	1.9	78
53	Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clinical Cancer Research, 2020, 26, 1220-1228.	3.2	77
54	Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer, 2006, 107, 1383-1390.	2.0	76

#	ARTICLE	IF	CITATIONS
55	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . <i>Clinical Cancer Research</i> , 2021, 27, 5236-5247.	3.2	74
56	<i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2475-2485.	1.9	73
57	Analysis of 1,115 Patients Tested for <i>MET</i> Amplification and Therapy Response in the MD Anderson Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 6336-6345.	3.2	70
58	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. <i>Oncology</i> , 2019, 97, 102-111.	0.9	67
59	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 4801-4810.	3.2	63
60	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015, 33, 621-631.	1.2	63
61	Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. <i>Clinical Cancer Research</i> , 2018, 24, 1138-1151.	3.2	63
62	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. <i>International Journal of Dermatology</i> , 2014, 53, 376-384.	0.5	62
63	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. <i>Oncotarget</i> , 2017, 8, 39254-39267.	0.8	62
64	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3263-3272.	3.2	61
65	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1237-1246.	3.2	61
66	Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience. <i>Oncologist</i> , 2011, 16, 1292-1298.	1.9	60
67	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 460-467.	1.9	60
68	Histology-agnostic drug development "considering issues beyond the tissue. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 555-568.	12.5	60
69	Mechanisms of Resistance to KRASG12C-Targeted Therapy. <i>Cancer Discovery</i> , 2021, 11, 1345-1352.	7.7	60
70	Intratumoral Injection of <i>Clostridium novyi</i> -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 96-106.	3.2	59
71	STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia. <i>Oncologist</i> , 2014, 19, 536-544.	1.9	55
72	Prevalence of complementary medicine use in a phase 1 clinical trials program. <i>Cancer</i> , 2011, 117, 5142-5150.	2.0	53

#	ARTICLE	IF	CITATIONS
73	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. <i>Oncotarget</i> , 2016, 7, 54627-54631.	0.8	53
74	Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1001-1006.	1.9	51
75	cMET Exon 14 Skipping: From the Structure to the Clinic. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1423-1432.	0.5	51
76	Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib. <i>Archives of Dermatology</i> , 2008, 144, 779-82.	1.7	50
77	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. <i>Cancer</i> , 2016, 122, 3401-3409.	2.0	50
78	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.	3.2	50
79	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.	3.2	50
80	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. <i>PLoS ONE</i> , 2014, 9, e89388.	1.1	50
81	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 118-128.	3.0	49
82	Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs. <i>Clinical Cancer Research</i> , 2014, 20, 281-288.	3.2	46
83	A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 407-418.	1.1	46
84	Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. <i>Clinical Cancer Research</i> , 2020, 26, 4531-4541.	3.2	46
85	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 162, 60-67.	0.3	45
86	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015, 6, 26886-26894.	0.8	45
87	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	0.8	44
88	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and <i>PIK3CA</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2857-2863.	1.9	42
89	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3802-3810.	3.2	42
90	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. <i>Oncologist</i> , 2021, 26, 588-596.	1.9	42

#	ARTICLE	IF	CITATIONS
91	Exosome-mediated drug resistance in cancer: the near future is here. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 320-322.	1.4	41
92	Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. <i>Science Advances</i> , 2020, 6, eaay6298.	4.7	41
93	Therapeutics Targeting Mutant KRAS. <i>Annual Review of Medicine</i> , 2021, 72, 349-364.	5.0	41
94	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.	3.2	40
95	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. <i>Cancer Immunology Research</i> , 2020, 8, 1365-1380.	1.6	37
96	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3845-3856.	3.2	35
97	Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. <i>British Journal of Cancer</i> , 2020, 123, 1496-1501.	2.9	35
98	Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-102.	0.8	35
99	First-in-human, phase I study of PF06647263, an anti-FNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019, 145, 1798-1808.	2.3	34
100	First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE <sub>2</sub> -receptor E-type 4 (EP4), in patients with advanced cancers. , 2020, 8, e000222.		34
101	Moving Beyond 3+3: The Future of Clinical Trial Design. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e133-e144.	1.8	33
102	Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4423-4432.	1.8	32
103	Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib. <i>JAMA Dermatology</i> , 2013, 149, 322.	2.0	32
104	Comprehensive Clinical and Molecular Characterization of KRAS <sup>G12C</sup> -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	1.5	31
105	Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4974-4982.	3.2	30
106	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5781-5792.	3.2	30
107	A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11514-11514.	0.8	30
108	Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. <i>Clinical Cancer Research</i> , 2017, 23, 1414-1421.	3.2	29

#	ARTICLE	IF	CITATIONS
109	Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open, 2016, 1, e000055.	2.0	28
110	A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nature Biomedical Engineering, 2021, 5, 297-308.	11.6	28
111	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer, 2014, 120, 2164-2173.	2.0	27
112	A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 918-926.	1.2	26
113	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer, 2015, 15, 61.	1.1	25
114	Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discovery, 2017, 7, 558-560.	7.7	25
115	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clinical Cancer Research, 2021, 27, 3050-3060.	3.2	24
116	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget, 2015, 6, 18693-18706.	0.8	24
117	A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 167-177.e2.	0.9	21
118	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports, 2017, 7, 15963.	1.6	21
119	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience, 2017, 4, 47-56.	0.9	21
120	Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors. Clinical Cancer Research, 2013, 19, 4824-4831.	3.2	20
121	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clinical Cancer Research, 2021, 27, 1864-1874.	3.2	20
122	Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology, 2017, 283, 314-340.	3.6	19
123	Improving attribution of adverse events in oncology clinical trials. Cancer Treatment Reviews, 2019, 76, 33-40.	3.4	19
124	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. British Journal of Cancer, 2022, 126, 514-520.	2.9	19
125	First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2508-2508.	0.8	19
126	Untying the gordian knot of targeting MET in cancer. Cancer Treatment Reviews, 2018, 66, 95-103.	3.4	18



#	ARTICLE	IF	CITATIONS
127	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2022, , .	1.9	18
128	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. <i>Investigational New Drugs</i> , 2018, 36, 416-423.	1.2	17
129	Phase I Study of P-cadherinâ€‘targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5830-5842.	3.2	17
130	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. <i>Oncotarget</i> , 2016, 7, 64421-64430.	0.8	17
131	Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	16
132	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	3.2	16
133	Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 824-824.	0.8	16
134	Engineered T-cell Receptor T Cells for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 1252-1261.	1.6	16
135	Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 479-488.	3.2	16
136	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administrationâ€‘Approved Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 4031-4037.	3.2	15
137	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1165-1172.	1.9	15
138	Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, C43-C43.	1.9	15
139	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
140	Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. <i>Clinical Cancer Research</i> , 2017, 23, 4020-4026.	3.2	14
141	Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. <i>International Journal of Cancer</i> , 2020, 146, 3450-3460.	2.3	14
142	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCOâ€‘Friends of Cancer Research Prior Therapies Work Group. <i>Clinical Cancer Research</i> , 2021, 27, 2408-2415.	3.2	14
143	A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. <i>Oncotarget</i> , 2014, 5, 11154-11167.	0.8	14
144	A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 955-963.	1.1	13

#	ARTICLE	IF	CITATIONS
145	Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in <i>KIT</i> -Mutant Melanoma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-8.	1.5	13
146	Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 428-440.	1.3	13
147	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10348.	2.1	13
148	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016, 6, 35448.	1.6	12
149	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021, 5, 21.	2.3	12
150	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. <i>Clinical Cancer Research</i> , 2017, 23, 1407-1413.	3.2	11
151	Basket Designs: Statistical Considerations for Oncology Trials. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	11
152	Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. , 2022, 10, e004822.		11
153	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 5956-5963.	3.2	10
154	A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. <i>Targeted Oncology</i> , 2021, 16, 569-589.	1.7	10
155	Basket Trials: Review of Current Practice and Innovations for Future Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 3520-3528.	0.8	10
156	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1759-1769.	2.0	9
157	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. <i>Current Problems in Cancer</i> , 2021, 45, 100734.	1.0	9
158	Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 Skipping. <i>JCO Precision Oncology</i> , 2021, 5, 1802-1812.	1.5	9
159	Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 963-970.	1.2	8
160	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 215-224.	1.2	8
161	Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. <i>ELife</i> , 2021, 10, .	2.8	8
162	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With <i>MAGE-A10+</i> Head and Neck, Melanoma, or Urothelial Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 818679.	1.3	8

#	ARTICLE	IF	CITATIONS
163	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. <i>British Journal of Cancer</i> , 2018, 118, 1419-1424.	2.9	7
164	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	1.5	7
165	Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). , 2019, , .		7
166	Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3056-3056.	0.8	7
167	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. <i>Oncoscience</i> , 2014, 1, 522-530.	0.9	7
168	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100262.	0.6	7
169	Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2022, 165, 664-670.	0.6	7
170	Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. <i>Clinical Colorectal Cancer</i> , 2012, 11, 297-303.	1.0	6
171	METin ovarian cancer: Metastasis and resistance?. <i>Cell Cycle</i> , 2014, 13, 1220-1221.	1.3	6
172	Specific learning disorders in sex chromosome aneuploidies: Neural circuits of literacy and mathematics. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2020, 184, 518-530.	0.7	6
173	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i> mutated advanced cancers. <i>Cancer</i> , 2021, 127, 391-402.	2.0	6
174	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	1.0	5
175	Molecular Imaging with 3-deoxy-3-[(18F)-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. <i>Diagnostics</i> , 2020, 10, 125.	1.3	5
176	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor~positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	3.2	5
177	Accreditation Program for Excellence (APEX): A Catalyst for Quality Improvement. <i>Practical Radiation Oncology</i> , 2021, 11, 101-107.	1.1	5
178	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.	1.9	5
179	379-Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8± co-receptor. , 2020, , .		5
180	Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib. <i>Cancer Genetics</i> , 2022, 260-261, 46-52.	0.2	5

#	ARTICLE	IF	CITATIONS
181	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. <i>Clinical Cancer Research</i> , 2017, 23, 4155-4162.	3.2	4
182	A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3091-3091.	0.8	4
183	387â€¦A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. , 2020, , .		4
184	A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 845417.	2.2	3
185	Dyslexia in Pediatrics: Simple Practices to Tackle a Complex Issue. <i>Pediatrics</i> , 2020, 146, e20201470.	1.0	2
186	Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 157-162.	1.2	2
187	Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center. <i>American Journal of Surgery</i> , 2022, 223, 539-542.	0.9	2
188	Targeting translation initiation in breast cancer. <i>Translation</i> , 2014, 2, e28968.	2.9	1
189	Phase I Trial: SABR and Ipilimumabâ€™Response. <i>Clinical Cancer Research</i> , 2017, 23, 321-321.	3.2	1
190	RADI-03. ASL PERFUSION IMAGING OF THE FRONTAL LOBES PREDICTS THE OCCURRENCE AND RESOLUTION OF POSTERIOR FOSSA SYNDROME. <i>Neuro-Oncology</i> , 2018, 20, i170-i170.	0.6	1
191	Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. <i>Investigational New Drugs</i> , 2020, 38, 1166-1174.	1.2	1
192	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e001073.	2.0	1
193	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	0.9	1
194	Abstract B56: A phase 1, open-label, dose escalation, nonrandomized study to assess the maximum tolerated dose, dose limiting toxicity, and pharmacokinetics of OPB-31121 in subjects with advanced solid tumors.. , 2011, , .		1
195	Abstract 2687: Development of a new, highly sensitive assay for circulating tumor cell (CTC) detection based on the CellSearchÂ® CTC Profile Kit enrichment and laser scanning cytometry analysis. <i>Cancer Research</i> , 2010, 70, 2687-2687.	0.4	1
196	Considerations for the Attribution and Management of Toxicities in Phase I Clinical Trials. , 2020, , 109-118.		1
197	A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, , 1.	1.2	0
198	This Changes Everything, Twice!. <i>Science Translational Medicine</i> , 2011, 3, .	5.8	0

#	ARTICLE	IF	CITATIONS
199	Patient, Heal Thyself. Science Translational Medicine, 2011, 3, .	5.8	0
200	A Fountain of Cancer. Science Translational Medicine, 2011, 3, .	5.8	0
201	A Hair-Raising Finding in Leukemia. Science Translational Medicine, 2011, 3, .	5.8	0
202	Old Dogs and New Tricks. Science Translational Medicine, 2011, 3, .	5.8	0
203	A Death by a Thousand Cuts. Science Translational Medicine, 2011, 3, .	5.8	0
204	A Picture Is Worth a Thousand Dollars?. Science Translational Medicine, 2011, 3, .	5.8	0
205	Good Ideas Come in Small Packages. Science Translational Medicine, 2011, 3, .	5.8	0
206	The Great Escape. Science Translational Medicine, 2011, 3, .	5.8	0
207	Putting Out the Fire. Science Translational Medicine, 2011, 3, .	5.8	0
208	Another Window of Opportunity. Science Translational Medicine, 2012, 4, .	5.8	0
209	The Mutation That Broke the Cell's Back. Science Translational Medicine, 2012, 4, .	5.8	0